Entries by

AnPac Bio Validating Approved COVID-19 Antibody Test

FOR IMMEDIATE RELEASE AnPac Bio Validating Approved COVID-19 Antibody Test San Jose, CA, August 7, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States announced today that the Company has been validating an approved COVID-19 antibody test, which […]

AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectiveness

FOR IMMEDIATE RELEASE AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectiveness San Jose, CA, August 4, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced […]

AnPac Bio Completes Over 180,000 CDA-Based Cancer Risk Assessment Tests

AnPac Bio Completes Over 180,000 CDA-Based Cancer Risk Assessment Tests San Jose, CA, July 29, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it had completed over 180,000 Cancer […]

AnPac Bio Completed 1st Half Year with Increased ASP and Revenue

FOR IMMEDIATE RELEASE AnPac Bio Completed 1st Half Year with Increased ASP and Revenue San Jose, CA, July 13, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, pre-announced certain results […]

AnPac Bio Ranked #3 in Liquid Biopsy Clinical Samples Globally by Frost & Sullivan While Retaining #1 Position and Widening its Lead in China in Cancer Screening

FOR IMMEDIATE RELEASE AnPac Bio Ranked #3 in Liquid Biopsy Clinical Samples Globally by Frost & Sullivan While Retaining #1 Position and Widening its Lead in China in Cancer Screening San Jose, CA, June 26, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations […]

AnPac Bio Launches New Immunology Test Product Line

FOR IMMEDIATE RELEASE AnPac Bio Launches New Immunology Test Product Line San Jose, CA, June 22, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that  the Company launched […]

AnPac Bio Signs a Record Multi-Million Dollar Contract for Cancer Screening

FOR IMMEDIATE RELEASE AnPac Bio Signs a Record Multi-Million Dollar Contract for Cancer Screening San Jose, CA, June 19, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that […]

AnPac Bio Announces Appointment of New Chief Financial Officer

San Jose, CA, June 2, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced the appointment of Mr. Jinqiu (Edwards) Tang as the Chief Financial Officer of the Company, […]

AnPac Bio Continues to Build Strong Patent Portfolio, with 3rd Patent Granted This Year in the United States

AnPac Bio Continues to Build Strong Patent Portfolio, with 3rd Patent  Granted This Year in the United States San Jose, CA, May 26, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and […]

AnPac Bio Reports Record Revenue and Number of Cancer Risk Assessment Tests in 2019  

AnPac Bio Reports Record Revenue and Number of Cancer Risk Assessment Tests in 2019   Continued annual revenue growth Number of commercial CDA (cancer differentiation analysis)-based tests increased 26.0% year-on-year Continued to gain customers and increase the acceptance of our cancer risk assessment tests San Jose, CA, May 18, 2020 – AnPac Bio-Medical Science Co., […]

©2019 Anpac Bio-Medical Science Co., Ltd.